AWH - Aspira Women's Health Inc Debt to Book Capitalization Ratio

Graphic logo of Aspira Women's Health (AWH)

Aspira Women's Health is advancing oncology diagnostics, strengthening its position through FDA certifications. The percentage of debt participation in balance sheet capital demonstrates reliability dynamics, where the value of 0.00 characterizes this level. The financial base relies on alliances with clinics, and localization in the US minimizes geopolitical risks, limiting them only to a possible shortage of Asian consumables.

Aspira Women's Health - AWH Debts to Book Capitalization (period 07/04/2022 - 04/26/2025)
Flagship merchandise of Vermillion

This ratio determines the proportion of borrowed liabilities relative to the company's total equity. It measures the degree of financial leverage and the company's dependence on external borrowing. For Aspira Women's Health (AWH), this balance is critical when scaling the OVA1 diagnostic platform. Stable demand for molecular tests allows the company to control its debt load. By analyzing the dynamics of the debt-to-equity ratio, an investor can assess the risks of asset impairment.

Who Aspira Women's Health competes with

Debts to Book Capitalization A (Agilent Technologies)|questdiagnostics.com - Debts to Book Capitalization|Illumina (ILMN) - Debt to Book Capitalization Ratio|EXAS - Debt to Book Value Ratio|RVTY: Debts to Book Capitalization|BIO (Bio-Rad Corp) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Anbio Biotechnology|Debt to Book Capitalization Ratio soterahealth.com (SHC)|QuidelOrtho Corporation - Debt to Book Value|Debts to Book Value OPK (OPKO Health Inc)|Debt to Book Capitalization Ratio CDNA|Debts to Net Assets Maravai MRVI|Debts to Book Capitalization FLGT (Fulgent Genetics, Inc.)|LAB: Debts to Net Assets|Cytek Biosciences - Debt to Book Capitalization Ratio|OraSure Technologies, Inc. (OSUR) - Debts to Net Assets|XGN (Exagen Inc) - Debts to Book Capitalization|Debts to Book Capitalization MDXH|LUCD (Lucid Diagnostics Inc.) - Debt to Book Capitalization Ratio|Debts to Net Assets PRE (prenetics.com)|Insight Molecular Diagnostics Inc (IMDX) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio Trinity Biotech PLC TRIB|Debts to Book Capitalization PRPH (ProPhase)|AIMD: Debts to Net Assets|Debt to Book Capitalization Ratio Co-Diagnostics, Inc. CODX|heartsciences.com (HSCS) - Debt to Net Assets Ratio|BMRA (Biomerica) - Debts to Book Capitalization|Debts to Book Capitalization Cardio Diagnostics Holdings, Inc. (CDIO)|Virax Biolabs Group Ltd (VRAX) - Debt to Book Value|Debt to Net Assets Ratio Bluejay Diagnostics Corp BJDX|Accelerate Diagnostics - Debt to Book Value|centogene.com - Debt to Book Value|ENZ (Enzo) - Debt to Book Capitalization Ratio|FRES: Debts to Book Value|GENE (gtglabs.com) - Debt to Book Capitalization Ratio|23andMe Inc (ME) - Debt to Book Value|Debts to Book Capitalization PMD (Psychemedics)